医学
内科学
冲程(发动机)
心力衰竭
急性冠脉综合征
心脏病学
比率
心源性猝死
置信区间
心肌梗塞
机械工程
工程类
作者
Jie Yu,Clare Arnott,Qiang Li,Gian Luca Di Tanna,Maoyi Tian,Liping Huang,Xuejun Yin,X. Zhang,Sallie‐Anne Pearson,Darwin R. Labarthe,Paul Elliott,Lijing L. Yan,Bo Zhou,Yangfeng Wu,Bruce Neal
出处
期刊:Hypertension
[Ovid Technologies (Wolters Kluwer)]
日期:2024-03-11
标识
DOI:10.1161/hypertensionaha.123.22410
摘要
Background: The SSaSS (Salt Substitute and Stroke Study) has shown that use of a potassium-enriched salt lowers the risk of stroke, total cardiovascular events, and premature death. The effects on cause-specific cardiac outcomes are reported here. Methods: SSaSS was an unblinded, cluster-randomised trial assessing the effects of potassium-enriched salt compared with regular salt among 20 995 Chinese adults with established stroke and older age and uncontrolled hypertension. Post hoc efficacy analyses were performed using an intention-to-treat method and a hierarchical Poisson regression model adjusting for clustering to obtain rate ratios and 95% CIs. We assessed acute coronary syndrome, heart failure, arrhythmia, and sudden death. Results: Over a mean 4.74 years follow-up, there were 695 acute coronary syndrome events, 454 heart failure events, 230 arrhythmia events, and 1133 sudden deaths recorded. The rates of events were lower in potassium-enriched salt group for all outcomes but CIs were wide for most: acute coronary syndrome (6.32 versus 7.65 events per 1000 person-years; rate ratio, 0.80 [95% CI, 0.65–0.99]); heart failure (9.14 versus 11.32 events per 1000 person-years; rate ratio, 0.88 [95% CI, 0.60–1.28]); arrhythmia (4.43 versus 6.20 events per 1000 person-years; rate ratio, 0.59 [95% CI, 0.35–0.98]); and sudden death (11.01 versus 11.76 events per 1000 person-years; rate ratio, 0.94 [95% CI, 0.82–1.07]; all P >0.05 with adjustment for multiple comparisons). Conclusions: These results suggest that use of potassium-enriched salt is more likely to prevent than cause cardiac disease but the post hoc nature of these analyses precludes definitive conclusions. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02092090.
科研通智能强力驱动
Strongly Powered by AbleSci AI